Transgenic mice overexpressing miR-137 in the brain show schizophrenia-associated behavioral deficits and transcriptome profiles.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2019
Historique:
received: 17 01 2019
accepted: 14 07 2019
entrez: 31 7 2019
pubmed: 31 7 2019
medline: 11 3 2020
Statut: epublish

Résumé

Schizophrenia is a psychiatric disorder characterized by positive and negative symptoms and cognitive deficits. The exact cause of schizophrenia is still unknown, but substantial evidence indicates that it has a genetic component. Genome wide association studies demonstrate variants within miR-137 host gene are a risk factor for schizophrenia. However, the direct relationship between the pathophysiology of schizophrenia and the dosage of miR-137 remains unclear. Therefore, in this study, we generated transgenic mice overexpressing miR-137 (miR-137 Tg mice) with the neuron-specific Thy-1 promoter and examined schizophrenia-related phenotypes in these mice. Overexpression of miR-137 was observed in various brain regions of the miR-137 Tg mice, with down-regulation of putative miR-137 targets. MiR-137 Tg mice showed sensory gating deficits in a prepulse inhibition test, social deficits in a sociability and social novelty test, and cognitive deficits in a novel object recognition test. Interestingly, the predicted-altered pathways of the medial prefrontal cortex of miR-137 Tg mice were partially overlapped with those of the dorsolateral prefrontal cortex in postmortem brain of patients who died in equal to or less than 4 years after initial diagnosis of schizophrenia in published data. These results suggest that overexpression of miR-137 in the whole brain induces the several phenotypes that are relevant to aspects of psychiatric disorders, such as schizophrenia. Based on these findings, miR-137 Tg mice may have the potential to become a useful tool in researching the pathophysiology of psychiatric disorders.

Identifiants

pubmed: 31361772
doi: 10.1371/journal.pone.0220389
pii: PONE-D-19-01670
pmc: PMC6667145
doi:

Substances chimiques

MIRN137 microRNA, mouse 0
MicroRNAs 0
Thy-1 Antigens 0

Banques de données

Dryad
['10.5061/dryad.3jk4mj2']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0220389

Déclaration de conflit d'intérêts

All the authors are employed by Takeda Pharmaceutical Company Limited. There are no patents to declare. Takeda Pharmaceutical Company Limited does not alter our adherence to all the PLOS ONE policies on sharing data and materials.

Références

J Biomed Inform. 2011 Oct;44(5):839-47
pubmed: 21605702
Mol Psychiatry. 2013 Apr;18(4):443-50
pubmed: 23459466
Lancet Psychiatry. 2015 Mar;2(3):258-270
pubmed: 26359903
Trends Cogn Sci. 2012 Nov;16(11):559-72
pubmed: 23047070
Brain Res. 2008 Nov 6;1239:235-48
pubmed: 18778695
Schizophr Bull. 2018 Jan 13;44(1):168-181
pubmed: 28338943
Trends Neurosci. 2002 Jul;25(7):340-3
pubmed: 12079756
Arch Gen Psychiatry. 1986 Feb;43(2):114-24
pubmed: 3947207
Biol Psychiatry. 2011 Jan 15;69(2):180-7
pubmed: 21111402
Pharmacol Ther. 2009 May;122(2):150-202
pubmed: 19269307
Nature. 2008 Sep 11;455(7210):237-41
pubmed: 18668038
Schizophr Bull. 2016 Jul;42(4):1003-8
pubmed: 26429811
Mol Psychiatry. 2017 Jan;22(1):44-55
pubmed: 27620842
Mol Psychiatry. 2013 Jul;18(7):774-80
pubmed: 22733126
EMBO J. 1990 Mar;9(3):833-40
pubmed: 1968831
Cell Stem Cell. 2017 Sep 7;21(3):305-318.e8
pubmed: 28803920
Curr Top Behav Neurosci. 2016;28:305-25
pubmed: 27311762
Nat Genet. 2011 Sep 18;43(10):969-76
pubmed: 21926974
Nat Neurosci. 2015 Jul;18(7):1008-16
pubmed: 26005852
J Psychiatr Res. 2013 Sep;47(9):1215-21
pubmed: 23786914
N Engl J Med. 2003 Oct 30;349(18):1738-49
pubmed: 14585943
Nature. 2014 Jul 24;511(7510):421-7
pubmed: 25056061
Front Genet. 2015 Apr 20;6:147
pubmed: 25941532
CNS Drugs. 2014 Apr;28(4):301-18
pubmed: 24526625
Mol Psychiatry. 2013 Jan;18(1):11-2
pubmed: 22182936
Prog Neuropsychopharmacol Biol Psychiatry. 2015 Aug 3;61:30-6
pubmed: 25797415
PLoS One. 2010 Sep 29;5(9):
pubmed: 20927376
Front Hum Neurosci. 2017 Feb 02;11:44
pubmed: 28210217
Eur Neuropsychopharmacol. 2014 May;24(5):759-73
pubmed: 24342774
Biol Psychiatry. 2001 Dec 1;50(11):884-97
pubmed: 11743943
Neurosci Biobehav Rev. 2016 Jun;65:185-94
pubmed: 27073049
Cell. 2009 Jan 23;136(2):215-33
pubmed: 19167326
J Psychiatr Res. 1998 May-Aug;32(3-4):133-41
pubmed: 9793866
Schizophr Bull. 2016 Nov;42(6):1517-1527
pubmed: 27190280
Sci Rep. 2017 Nov 10;7(1):15328
pubmed: 29127368
Nature. 2009 Aug 6;460(7256):748-52
pubmed: 19571811
EBioMedicine. 2016 Oct;12:133-142
pubmed: 27650867
Prog Neuropsychopharmacol Biol Psychiatry. 2018 Jan 3;80(Pt B):155-165
pubmed: 28645536
Brain Res Bull. 2018 Jul;141:27-34
pubmed: 28587862
Curr Top Behav Neurosci. 2012;12:251-318
pubmed: 22367921
Nature. 2011 Jul 27;477(7363):171-8
pubmed: 21796121
Mol Neurobiol. 2006 Oct;34(2):109-28
pubmed: 17220533
Schizophr Res. 2005 Apr 1;74(1):15-26
pubmed: 15694750
Biol Psychiatry. 2017 May 15;81(10):874-885
pubmed: 28434616
J Neurosci Methods. 1997 Jan;71(1):3-9
pubmed: 9125370

Auteurs

Yuuichi Arakawa (Y)

Neuroscience Drug Discovery Unit, Research, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan.

Kazumasa Yokoyama (K)

Integrated Technology Research Laboratories, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan.

Shinya Tasaki (S)

Integrated Technology Research Laboratories, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan.

Junichi Kato (J)

Neuroscience Drug Discovery Unit, Research, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan.

Kosuke Nakashima (K)

Neuroscience Drug Discovery Unit, Research, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan.

Michiyasu Takeyama (M)

Integrated Technology Research Laboratories, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan.

Atsushi Nakatani (A)

Neuroscience Drug Discovery Unit, Research, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan.

Motohisa Suzuki (M)

Neuroscience Drug Discovery Unit, Research, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH